VKTX250103C70000
- 0.16
- 0.000.00%
Viking Therapeutics Newsroom
Jefferies Maintains Viking Therapeutics(VKTX.US) With Buy Rating, Maintains Target Price $110
Viking Therapeutics: Strategic Growth and Strong Buy Rating Amidst Advancements in Obesity Drug Pipeline
BTIG Maintains Viking Therapeutics(VKTX.US) With Buy Rating, Maintains Target Price $125
H.C. Wainwright Maintains Viking Therapeutics(VKTX.US) With Buy Rating, Maintains Target Price $102
Oppenheimer Maintains Viking Therapeutics(VKTX.US) With Buy Rating, Maintains Target Price $164
Viking Therapeutics Analyst Ratings
H.C. Wainwright Maintains Viking Therapeutics(VKTX.US) With Buy Rating, Maintains Target Price $102
HC Wainwright & Co. Reiterates Buy on Viking Therapeutics, Maintains $102 Price Target
Truist Financial Maintains Viking Therapeutics(VKTX.US) With Buy Rating, Announces Target Price $120
A Quick Look at Today's Ratings for Viking Therapeutics(VKTX.US), With a Forecast Between $95 to $105
Viking Therapeutics: Strategic Positioning and Promising Development of Oral 2735 Drive Buy Rating
Viking Therapeutics Analyst Ratings
Analysts Offer Insights on Healthcare Companies: Lexicon Pharmaceuticals (LXRX), Arcutis Biotherapeutics (ARQT) and Viking Therapeutics (VKTX)
H.C. Wainwright Maintains Viking Therapeutics(VKTX.US) With Buy Rating, Maintains Target Price $102
B.Riley Financial Maintains Viking Therapeutics(VKTX.US) With Buy Rating, Maintains Target Price $109
BTIG Maintains Viking Therapeutics(VKTX.US) With Buy Rating, Maintains Target Price $125
B.Riley Financial Reaffirms Their Buy Rating on Viking Therapeutics (VKTX)
Viking Therapeutics Analyst Ratings
HC Wainwright & Co. Reiterates Buy on Viking Therapeutics, Maintains $102 Price Target
H.C. Wainwright Maintains Viking Therapeutics(VKTX.US) With Buy Rating, Maintains Target Price $102